Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in HIV-Associated Multicentric Castleman Disease
NCT00127569Phase 2Terminated
- Sponsor
- ANRS
- Start
- May 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in multicentric Castleman disease (MCD), sponsored by ANRS. Primary endpoint: Sustained response rate of multicentric Castleman disease at 60 days. Started May 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT00127569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127569.